Brent Warner
Keine laufenden Positionen mehr
Vermögen: 859 032 $ am 30.04.2024
Profil
Brent Warner served as Vice President-Gene Therapy & Rare Disease at Novartis Pharmaceuticals Canada, Inc. from 2019 to 2022.
He then became President-Gene Therapy at Poseida Therapeutics, Inc. from 2022 to 2024.
Mr. Warner obtained an undergraduate degree and an MBA from Northwood University (Michigan).
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.03.2024 | 419 040 ( 0,43% ) | 859 032 $ | 30.04.2024 |
Ehemalige bekannte Positionen von Brent Warner
| Unternehmen | Position | Ende |
|---|---|---|
| POSEIDA THERAPEUTICS, INC. | Corporate Officer/Principal | 01.04.2024 |
Novartis Pharmaceuticals Canada, Inc.
 Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Corporate Officer/Principal | 01.02.2022 |
Ausbildung von Brent Warner
| Northwood University (Michigan) | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Novartis Pharmaceuticals Canada, Inc.
Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Health Technology |